- 데이터 없음
한국어
- English
- 简体中文
- 繁体中文
- Français
- Русский
- Italiano
- 日本語
- 한국어
- Português
- Deutsch
- Español
- Türkçe
- Ελληνικά
- Nederlands
- Tiếng Việt
- Polski
Researchers from the Laser Processing Group of the IO-CSIC Institute of Optics in Spain report on the application of multi-purpose femtosecond laser interference in high-precision silicon nanostructures. The related research was published in Optics&Laser Technology with the title "Versatile femtosecond laser interference pattern applied to high precision nanostructured of silicon".Highlights:...
Modern laser technology urgently requires nonlinear optical materials that can generate coherent light through second harmonic generation. However, only a small portion of the nonlinear optical properties of non centrosymmetric crystal materials have been experimentally or theoretically studied, and exploration for high-performance nonlinear optical crystal materials is still very limited.Recentl...
Recently, researchers from Kaunas University of Technology (KTU) in Lithuania and the Tsukuba National Institute of Materials Science in Ibaraki, Japan, have collaborated to successfully develop a new type of nanolaser based on silver nanocubes.Although its structure is small and can only be observed through high-power microscopes, its potential application prospects are broad, and the research te...
Light has angular momentum properties. Circularly polarized or elliptically polarized beams carry spin angular momentum (SAM), while beams with helical phase wavefronts carry orbital angular momentum (OAM). During the interaction between light and particles, the transfer of angular momentum can generate optical torque, driving particles to rotate. Among them, the transfer of optical spin angular m...
On July 3rd local time, Swiss ophthalmic care giant Alcon announced the acquisition of Israeli medical technology company Belkin Vision and its laser equipment assets for treating glaucoma.The transaction includes a prepayment of $81 million, of which approximately $65 million is in cash. In addition, if Alcon can establish this technology as the preferred first-line treatment option for clinical ...